NCT04711603View on ClinicalTrials.gov

A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

PHASE3CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

January 16, 2021

Primary Completion Date

January 25, 2022

Study Completion Date

September 26, 2022

Conditions
Uremic Pruritus
Interventions
DRUG

MR13A9

Intravenous administration

DRUG

Placebo

Intravenous administration

Trial Locations (1)

Unknown

Research Site, Multiple Locations

Sponsors
All Listed Sponsors
lead

Kissei Pharmaceutical Co., Ltd.

INDUSTRY

NCT04711603 - A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. | Biotech Hunter | Biotech Hunter